ERYTECH adds a new product candidate to its Cancer Metabolism development portfolio Post author:admERY Post published:April 9, 2014 Post category:Newsroom ERYTECH announces the addition of a new product development candidate, erymethionase, to the company’s Cancer Metabolism product pipeline. You Might Also Like ERYTECH Provides Business Update and Financial Highlights for Q1 2017 May 18, 2017 ERYTECH Provides Update on the Announced Combination with PHERECYDES May 16, 2023 ERYTECH announces three data presentations at the 2015 AACR Annual Meeting March 24, 2015